Dual role of PPAR-γ in induction and expression of behavioral sensitization to cannabinoid receptor agonist WIN55,212-2

NeuroMolecular Medicine

Volumn 15, Issue 3, 2013, Pages 523-535

  Enayatfard, Leili ^a   Rostami, Farzaneh ^a   Nasoohi, Sanaz ^a   Oryan, Shahrbanoo ^b   Ahmadiani, Abolhassan ^a,c   Dargahi, Leila ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KHARAZMI UNIVERSITY   (Iran)

^c UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Behavioral sensitization; Cannabinoid; Neuroinflammation; PPAR ; WIN55,212 2

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CYCLOOXYGENASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEHAVIORAL SENSITIZATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DOSE ESCALATION; ENZYME ACTIVITY; IMMUNOBLOTTING; LOCOMOTION; LOW DRUG DOSE; MALE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PSYCHOSIS; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

ANIMALIA;

ANILIDES; ANIMALS; BENZOXAZINES; BIOLOGICAL MARKERS; CANNABINOIDS; CORPUS STRIATUM; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; INFLAMMATION; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENTRICULAR; LOCOMOTION; MALE; MORPHOLINES; NAPHTHALENES; PPAR GAMMA; PSYCHOMOTOR AGITATION; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881476626     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-013-8238-x     Document Type: Article

References (58)

1. Asanuma, M., Miyazaki, I., Higashi, Y., Tsujin, T., & Ogawa, N. (2004). Specific gene expression and possible involvement of inflammation in methamphetamine-induced neurotoxicity. Annals of the New York Academy of Sciences, 1025(1), 69-75.
2. 2 receptors. British journal of pharmacology, 166(4), 1474-1489.
3. Breidert, T., Callebert, J., Heneka, M., Landreth, G., Launay, J., & Hirsch, E. (2002). Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease. Journal of Neurochemistry, 82(3), 615-624.
4. Burstein, S. (2005). PPAR-[gamma]: A nuclear receptor with affinity for cannabinoids. Life Sciences, 77(14), 1674-1684.
5. Cárdenas, A., Moro, M. A., Hurtado, O., Leza, J. C., Lorenzo, P., Castrillo, A., et al. (2000). Implication of glutamate in the expression of inducible nitric oxide synthase after oxygen and glucose deprivation in rat forebrain slices. Journal of Neurochemistry, 74(5), 2041-2048.
6. Collino, M., Aragno, M., Mastrocola, R., Gallicchio, M., Rosa, A. C., Dianzani, C., et al. (2006). Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. European Journal of Pharmacology, 530(1), 70-80.
7. Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000). Inflammatory mechanisms in Alzheimer's disease: Inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. The Journal of neuroscience, 20(2), 558-567.
8. Crosby, M. B., Zhang, J., Nowling, T. M., Svenson, J. L., Nicol, C. J., Gonzalez, F. J., et al. (2006). Inflammatory modulation of PPAR [gamma] expression and activity. Clinical immunology, 118(2-3), 276-283.
9. Drews, E., Schneider, M., & Koch, M. (2005). Effects of the cannabinoid receptor agonist WIN 55,212-2 on operant behavior and locomotor activity in rats. Pharmacology, Biochemistry and Behavior, 80(1), 145-150.
10. Du, H., Chen, X., Zhang, J., & Chen, C. (2011). Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ. British Journal of Pharmacology, 163(7), 1533-1549.
11. Fakhfouri, G., Ahmadiani, A., Rahimian, R., Grolla, A. A., Moradi, F., & Haeri, A. (2012). WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway. Neuropharmacology, 63(4), 653-666.
12. Fernandez-Espejo, E., Ramiro-Fuentes, S., & Rodriguez de Fonseca, F. (2009). The absence of a functional peroxisome proliferator-activated receptor-alpha gene in mice enhances motor sensitizing effects of morphine, but not cocaine. Neuroscience, 164(2), 667-675.
13. Ferrario, C. R., Gorny, G., Crombag, H. S., Li, Y., Kolb, B., & Robinson, T. E. (2005). Neural and behavioral plasticity associated with the transition from controlled to escalated cocaine use. Biological Psychiatry, 58(9), 751-759.
14. Ferré, P. (2004). The biology of peroxisome proliferator-activated receptors. Diabetes, 53(suppl 1), S43-S50.
15. Frank, M. G., Watkins, L. R., & Maier, S. F. (2011). Stress- and glucocorticoid-induced priming of neuro inflammatory responses: Potential mechanisms of stress-induced vulnerability to drugs of abuse. Brain, Behavior, and Immunity, 25(Suppl 1), S21-S28. doi: 10.1016/j.bbi.2011.01.005.
16. Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry, 232(1), 54-61.
17. Gerdeman, G. L., Schechter, J. B., & French, E. D. (2007). Context-specific reversal of cocaine sensitization by the CB1 cannabinoid receptor antagonist rimonabant. Neuropsychopharmacology, 33(11), 2747-2759.
18. Herkenham, M., Lynn, A. B., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1991). Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. The Journal of neuroscience, 11(2), 563-583.
19. Hunter, R. L., Dragicevic, N., Seifert, K., Choi, D. Y., Liu, M., Kim, H. C., et al. (2007). Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. Journal of Neurochemistry, 100(5), 1375-1386.
20. Kauer, J. A. (2004). Learning mechanisms in addiction: Synaptic plasticity in the ventral tegmental area as a result of exposure to drugs of abuse. Annual Review of Physiology, 66, 447-475.
21. Landreth, G. E. M., & Heneka, T. (2001). Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiology of Aging, 22(6), 937-944.
22. Le Foll, B., Di Ciano, P., Panlilio, L. V., Goldberg, S. R., & Ciccocioppo, R. (2013). Peroxisome proliferator-activated receptor (Ppar) agonists as promising new medications for drug addiction: Preclinical evidence. Current Drug Targets (Epub ahead of print).
23. Maeda, T., Kiguchi, N., Fukazawa, Y., Yamamoto, A., Ozaki, M., & Kishioka, S. (2006). Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice. Neuropsychopharmacology, 32(5), 1133-1140.
24. Mao, D., & McGehee, D. S. (2010). Nicotine and behavioral sensitization. Journal of Molecular Neuroscience, 40(1), 154-163.
25. Marchalant, Y., Brothers, H., & Wenk, G. (2009). Cannabinoid agonist WIN-55,212-2 partially restores neurogenesis in the aged rat brain. Molecular Psychiatry, 14(12), 1068-1069.
26. Melis, M., Pillolla, G., Luchicchi, A., Muntoni, A. L., Yasar, S., Goldberg, S. R., et al. (2008). Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. The Journal of neuroscience, 28(51), 13985-13994.
27. Nakajima, A., Yamada, K., Nagai, T., Uchiyama, T., Miyamoto, Y., Mamiya, T., et al. (2004). Role of tumor necrosis factor-α in methamphetamine- induced drug dependence and neurotoxicity. The Journal of neuroscience, 24(9), 2212-2225.
28. Nestler, E. J., & Malenka, R. C. (2004). The addicted brain. Scientific American, 290(3), 78-85.
29. O'Brien, C. P. (1997). A range of research-based pharmacotherapies for addiction. Science, 278(5335), 66-70.
30. O'Sullivan, S. E. (2007). Cannabinoids go nuclear: Evidence for activation of peroxisome proliferator-activated receptors. British Journal of Pharmacology, 152(5), 576-582.
31. O'sullivan, S., Bennett, A., Kendall, D., & Randall, M. (2006). Cannabinoids and peroxisome proliferator-activated receptor gamma (PPARγ). Proceedings of the international cannabinoid research society (ICRS'06) (p. 59).
32. Pagano, C., Pilon, C., Calcagno, A., Urbanet, R., Rossato, M., Milan, G., et al. (2007). The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. Journal of Clinical Endocrinology and Metabolism, 92(12), 4810-4819.
33. Paxinos, G., & Watson, C. (2007). The rat brain in stereotaxic coordinates: Hard cover edition. London: Academic press.
34. Petitet, F., Jeantaud, B., Bertrand, P., & Imperato, A. (1999). Cannabinoid penetration into mouse brain as determined by ex vivo binding. European Journal of Pharmacology, 374(3), 417-421.
35. Pini, A., Mannaioni, G., Pellegrini-Giampietro, D., Beatrice Passani, M., Mastroianni, R., Bani, D., et al. (2012). The role of cannabinoids in inflammatory modulation of allergic respiratory disorders, inflammatory pain and ischemic stroke. Current Drug Targets, 13(7), 984-993.
36. Polissidis, A., Chouliara, O., Galanopoulos, A., Marselos, M., Papadopoulou-Daifoti, Z., & Antoniou, K. (2009). Behavioural and dopaminergic alterations induced by a low dose of WIN 55,212-2 in a conditioned place preference procedure. Life Sciences, 85(5-6), 248-254.
37. Quinn, L., Crook, B., Hows, M., Vidgeon-Hart, M., Chapman, H., Upton, N., et al. (2008). The PPARγ agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. British Journal of Pharmacology, 154(1), 226-233.
38. Randy, L. H., & Guoying, B. (2007). Agonism of peroxisome proliferator receptor-gamma may have therapeutic potential for neuroinflammation and Parkinson's disease. Current Neuropharmacology, 5(1), 35-46.
39. Rasmussen, B. A., Unterwald, E. M., Kim, J. K., & Rawls, S. M. (2010). Methanandamide blocks amphetamine-induced behavioral sensitization in rats. European Journal of Pharmacology, 627(1-3), 150-155.
40. Robinson, T. E., & Becker, J. B. (1986). Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. Brain Research Reviews, 11(2), 157-198.
41. Robinson, T. E., & Berridge, K. C. (2000). The psychology and neurobiology of addiction: An incentive-sensitization view. Addiction, 95(8s2), 91-117.
42. Saņudo-Peņa, M., Romero, J., Seale, G. E., Fernandez-Ruiz, J. J., & Walker, J. M. (2000). Activational role of cannabinoids on movement. European Journal of Pharmacology, 391(3), 269-274.
43. Steketee, J. D., & Kalivas, P. W. (2011). Drug wanting: Behavioral sensitization and relapse to drug-seeking behavior. Pharmacological Reviews, 63(2), 348-365.
44. Stopponi, S., Somaini, L., Cippitelli, A., Cannella, N., Braconi, S., Kallupi, M., et al. (2011). Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biological Psychiatry, 69(7), 642-649.
45. Sulcova, E., Mechoulam, R., & Fride, E. (1998). Biphasic effects of anandamide. Pharmacology, Biochemistry and Behavior, 59(2), 347-352.
46. Sun, Y., Alexander, S., Kendall, D., & Bennett, A. (2006). Cannabinoids and PPARalpha signalling. Biochemical Society Transactions, 34(Pt 6), 1095-1097.
47. Sundararajan, S., Jiang, Q., Heneka, M., & Landreth, G. (2006). PPAR [gamma] as a therapeutic target in central nervous system diseases. Neurochemistry International, 49(2), 136-144.
48. Tanda, G., Munzar, P., & Goldberg, S. R. (2000). Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nature Neuroscience, 3(11), 1073-1074.
49. Tanda, G., Pontieri, F. E., & Chiara, G. D. (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism. Science, 276(5321), 2048-2050.
50. Thiemann, G., Di Marzo, V., Molleman, A., & Hasenöhrl, R. U. (2008a). The CB < sub > 1 cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus. Pharmacology, Biochemistry and Behavior, 89(3), 384-391.
51. Thiemann, G., van der Stelt, M., Petrosino, S., Molleman, A., Di Marzo, V., & Hasenöhrl, R. U. (2008b). The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization. Behavioural Brain Research, 187(2), 289-296.
52. Vanderschuren, L. J., & Kalivas, P. W. (2000). Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: A critical review of preclinical studies. Psychopharmacology (Berl), 151(2), 99-120.
53. Vanderschuren, L. J., & Pierce, R. C. (2010). Sensitization processes in drug addiction. Behavioral Neuroscience of Drug Addiction, 3, 179-195.
54. Wegener, N., & Koch, M. (2009). Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. Brain Research, 1253, 81-91.
55. Wiley, J. L., Evans, R. L., Grainger, D. B., & Nicholson, K. L. (2011). Locomotor activity changes in female adolescent and adult rats during repeated treatment with a cannabinoid or club drug. Pharmacological Reports, 63(1085), 1085-1092.
56. Wolf, M. E., Sun, X., Mangiavacchi, S., & Chao, S. Z. (2004). Psychomotor stimulants and neuronal plasticity. Neuropharmacology, 47(Suppl 1), 61-79.
57. Zalcman, S., Savina, I., & Wise, R. A. (1999). Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats. Brain Research, 847(2), 276-283.
58. Zhu, J., & Reith, M. E. A. (2008). Role of dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. CNS and Neurological Disorders: Drug Targets, 7(5), 393-409.